Drug intelligence / Profile preview

SBT-121

Development stage: Preclinical
Lead developer: Shennon Biotechnologies
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SBT-121 is a trispecific antibody-based T-cell engager (Ab-TCE) being developed by Shennon Biotechnologies for the treatment of solid tumors, specifically small cell lung cancer (SCLC). The therapeutic candidate is designed to engage T-cells to target and eliminate cancer cells. SBT-121 is currently in the discovery and preclinical stage of development, and its specific molecular targets have not been publicly disclosed.

Beyond the preview

Go deeper on SBT-121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-121.

Explore the full profile